Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.63 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7389137 | 0.93 | GPR119 (0.55) | GPR119HRH3CHEK2ALDH1A1USP30 | |
| SCHEMBL6190259 | 0.93 | GPR119 (0.55) | GPR119HRH3CHEK2ALDH1A1USP30 | |
| SCHEMBL14636946 | 0.87 | USP30 (0.50) | GPR119HRH3CHEK2ALDH1A1USP30 | |
| SCHEMBL1035158 | 0.85 | GPR119 (0.53) | GPR119HRH3CHEK2USP30PDE4A | |
| SCHEMBL15571129 | 0.85 | GPR119 (0.58) | GPR119HRH3CHEK2ALDH1A1USP30 | |
| SCHEMBL23373811 | 0.85 | GPR119 (0.58) | GPR119HRH3CHEK2ALDH1A1USP30 | |
| SCHEMBL264162 | 0.85 | GPR119 (0.67) | GPR119HRH3CHEK2ALDH1A1USP30 | |
| SCHEMBL74203 | 0.85 | GPR119 (0.67) | GPR119HRH3CHEK2ALDH1A1USP30 | |
| SCHEMBL2735422 | 0.85 | GPR119 (0.67) | GPR119HRH3CHEK2ALDH1A1USP30 | |
| SCHEMBL12533230 | 0.85 | GPR119 (0.67) | GPR119CHEK2ALDH1A1PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606533-B2 | 3-phenylpropylamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-04-21 | — | — | US | disclosed |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-11-20 | — | — | US | disclosed |
| EP-4563573-A1 | COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF SEH INHIBITOR AND PPARS AGONIST | Shenyang Pharmaceutical University (CN) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024193129-A1 | COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF IN PREPARATION OF SEH INHIBITOR AND PPARS AGONIST | 沈阳药科大学 | 2024-09-26 | — | — | WO | disclosed |
| CN-118206473-A | Compound, preparation method thereof and application of compound in preparation of sEH inhibitor and PPARs agonist | 沈阳药科大学 | 2024-06-18 | — | — | CN | disclosed |
| CN-118206542-A | Compound, preparation method thereof and application of compound in preparation of sEH inhibitor and PPARs agonist | 沈阳药科大学 | 2024-06-18 | — | — | CN | disclosed |
| CN-118184545-A | Compound, preparation method thereof and application of compound in preparation of sEH inhibitor and PPARs agonist | 沈阳药科大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-116217511-B | Double-target compound, preparation method thereof and application thereof in preparation of sEH inhibitor and PPARs agonist | 沈阳药科大学 | 2024-04-19 | — | — | CN | disclosed |
| CN-116217511-A | Double-target compound, preparation method thereof and application thereof in preparation of sEH inhibitor and PPARs agonist | 沈阳药科大学 | 2023-06-06 | — | — | CN | disclosed |
| EP-3189059-B1 | THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS | ST EUROPEO DI ONCOLOGIA S R L (IT) | 2023-02-22 | — | — | EP | disclosed |
| WO-2007075629-A2 | PHENOXYPIPERIDINES AND ANALOGS THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | EISAI CO., LTD. (JP) | 2006-06-01 | — | — | US | disclosed |
| US-20060025404-A1 | Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1577288-A1 | SELECTIVE ESTROGEN RECEPTOR MODULATORS | Eisai Co., Ltd. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1567511-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2005-08-31 | — | — | EP | disclosed |
| US-6825191-B2 | ANTICOAGULANT | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| WO-2004035556-A1 | SUBSTITUTED PIPERAZINES, (1,4) DIASZEPINES, AND 2,5-DIAZABICYCLO (2.2.1) HEPTANES AS HISTAMINE H1 AND/OR H3 ANTAGONISTS OR HISTAMINE H3 REVERSE ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2004-04-29 | — | — | WO | disclosed |
| US-20030186969-A1 | Benzodiazepine derivatives | AJINOMOTO CO. INC (JP) | 2003-10-02 | — | — | US | disclosed |
| EP-1329450-A1 | BENZODIAZEPINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2003-07-23 | — | — | EP | disclosed |
| US-6037334-A | INHIBITORS OF FACTOR XA THAT CAN BE USED TO PREVENT DISEASES SUCH ASTHROMBOSIS, APOPLEXY, CORONARY INFARCTION, INFLAMMATIONS, AND ARTERIOSCLEROSIS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025404-A1 | Substituted piperazines,(1,4) diaszepines, and 2,5-diazabicyclo (2.2.1)iieptanes as histamine h1 and/or h3 antagonists or histamine h3 reverse antagonists | HRH3, HRH4, HRH2 | GPR119 213/4885HRH3 1/4885CHEK2 2039/4885 |
| US-20250353824-A1 | 3-PHENYLPROPYLAMINE DERIVATIVE | SF1, SF3A1, SFXN1 | GPR119 1338/4885HRH3 2393/4885CHEK2 4187/4885 |
| US-20030186969-A1 | Benzodiazepine derivatives | GABRA1, F11, GABRA4 | GPR119 501/4885HRH3 418/4885CHEK2 4655/4885 |
| US-12606533-B2 | 3-phenylpropylamine derivative | SF3A1, SF1, HTR1D | GPR119 467/4885HRH3 3294/4885CHEK2 4411/4885 |
| US-20060116364-A1 | Such as (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino }-4-methoxyphenyl }-5,6,7,8-tetrahydronaphthalen-2-ol; osteoporosis; breast cancer | BRCA1, BCR, RCC1 | GPR119 1708/4885HRH3 114/4885CHEK2 849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.